Literature DB >> 7683329

A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

A Stevens1, M Weller, H Wiethölter.   

Abstract

Paired cerebrospinal fluid and serum samples of patients with amyotrophic lateral sclerosis (n = 35) revealed no consistent abnormalities of CSF cell count, CSF albumin, CSF IgG, CSF IgM, IgG or IgM index, or oligoclonal immunoglobulin band formation in the CSF. Determination of IgG and IgM CSF and serum antibodies to gangliosides GM1, GM2, GM3, AGM1, GD1a, GD1b, and GT1b showed a characteristic pattern which allowed the differentiation of amyotrophic lateral sclerosis from controls and from patients with other neurological disorders including multiple sclerosis. Specifically, patients with the disease had elevated CSF IgM antibodies to all gangliosides except AGM1. The lack of correlation between the CSF findings and corresponding serum antibodies suggests a chronic, compartmental, intrathecal immune response of low activity in amyotrophic lateral sclerosis. Whether this immune response is primary and of pathogenetic significance, or an epiphenomenon of neuronal degeneration, remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683329      PMCID: PMC1014951          DOI: 10.1136/jnnp.56.4.361

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  26 in total

1.  Glutaraldehyde-enhanced immunofixation: a sensitive new method for detecting oligoclonal immunoglobulin M.

Authors:  M K Sharief; G Keir; E J Thompson
Journal:  J Neuroimmunol       Date:  1989-07       Impact factor: 3.478

2.  Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants.

Authors:  E F Salazar-Grueso; M J Routbort; J Martin; G Dawson; R P Roos
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

3.  Evidence for immune-complex formation in patients with amyotrophic lateral sclerosis.

Authors:  M B Oldstone; C B Wilson; L H Perrin; F H Norris
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

Review 4.  Amyotrophic lateral sclerosis: an unconventional autoimmune disease?

Authors:  D B Drachman; R W Kuncl
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

5.  Measurement and significance of antibodies against GM1 ganglioside. Report of a workshop, 18 April 1989, Chicago, IL, U.S.A.

Authors:  D M Marcus; N Latov; B P Hsi; B K Gillard
Journal:  J Neuroimmunol       Date:  1989-12       Impact factor: 3.478

6.  Immunoglobulin M in the cerebrospinal fluid: an indicator of recent immunological stimulation.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

7.  Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis.

Authors:  D Troost; J J van den Oord; J M de Jong; D F Swaab
Journal:  Clin Neuropathol       Date:  1989 Nov-Dec       Impact factor: 1.368

8.  The spectrum of neurologic disease associated with anti-GM1 antibodies.

Authors:  S A Sadiq; F P Thomas; K Kilidireas; S Protopsaltis; A P Hays; K W Lee; S N Romas; N Kumar; L van den Berg; M Santoro
Journal:  Neurology       Date:  1990-07       Impact factor: 9.910

9.  Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes.

Authors:  D S Younger; L P Rowland; N Latov; W Sherman; M Pesce; D J Lange; W Trojaborg; J R Miller; R E Lovelace; A P Hays
Journal:  Neurology       Date:  1990-04       Impact factor: 9.910

10.  Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.

Authors:  A Pestronk; V Chaudhry; E L Feldman; J W Griffin; D R Cornblath; E H Denys; M Glasberg; R W Kuncl; R K Olney; W C Yee
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

View more
  10 in total

Review 1.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Antiganglioside antibodies in the CSF of patients with motor neuron diseases and Guillain-Barré syndrome.

Authors:  C Iñiguez; A Jiménez-Escrig; J M Gobernado; M Nocito; P Gonzalez-Porque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

Review 4.  Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders.

Authors:  P Fredman; A Lekman
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

5.  Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis.

Authors:  James C Dodge; Christopher M Treleaven; Joshua Pacheco; Samantha Cooper; Channa Bao; Marissa Abraham; Mandy Cromwell; S Pablo Sardi; Wei-Lien Chuang; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

6.  Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia.

Authors:  Jin-Yue Li; Zheng-Yi Cai; Xiao-Han Sun; Dong-Chao Shen; Xun-Zhe Yang; Ming-Sheng Liu; Li-Ying Cui
Journal:  Neurol Sci       Date:  2021-11-26       Impact factor: 3.830

7.  GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons.

Authors:  Eun S Chung; Eugene Bok; Sunghyang Sohn; Young D Lee; Hyung H Baik; Byung K Jin
Journal:  BMC Neurosci       Date:  2010-06-12       Impact factor: 3.288

8.  Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis.

Authors:  Y Tsuboi; T Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

Review 9.  Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration.

Authors:  Tobias Moll; Pamela J Shaw; Johnathan Cooper-Knock
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

10.  Myelin- and microbe-specific antibodies in Guillain-Barré syndrome.

Authors:  J Terryberry; M Sutjita; Y Shoenfeld; B Gilburd; D Tanne; M Lorber; I Alosachie; N Barka; H C Lin; P Youinou
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.